A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
A multicentre prospective, randomised, phase II interventional study in mCRPC patients
previously treated with 1-2 lines of chemotherapy and at least 12 weeks of abiraterone with a
safety run-in and single stage phase II expansion cohort.